Sofinnova Investments Inc. increased its stake in shares of Immatics N.V. (NASDAQ:IMTX – Free Report) by 54.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,435,542 shares of the company’s stock after buying an additional 1,207,705 shares during the quarter. Immatics comprises approximately 1.5% of Sofinnova Investments Inc.’s investment portfolio, making the stock its 20th biggest position. Sofinnova Investments Inc. owned about 2.83% of Immatics worth $36,073,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Bank of America Corp DE grew its position in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Quarry LP acquired a new stake in Immatics during the fourth quarter worth approximately $84,000. Insigneo Advisory Services LLC acquired a new stake in Immatics during the third quarter worth approximately $103,000. Fox Run Management L.L.C. acquired a new stake in Immatics during the fourth quarter worth approximately $129,000. Finally, Engineers Gate Manager LP acquired a new stake in Immatics during the second quarter worth approximately $124,000. Institutional investors and hedge funds own 64.41% of the company’s stock.
Immatics Stock Up 0.5%
NASDAQ IMTX opened at $9.43 on Tuesday. Immatics N.V. has a twelve month low of $5.05 and a twelve month high of $12.41. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -4.74 and a beta of 1.30. The business’s fifty day moving average is $10.77 and its 200 day moving average is $10.24.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on IMTX shares. Weiss Ratings reissued a “sell (d)” rating on shares of Immatics in a research report on Tuesday, June 9th. Mizuho set a $25.00 price target on Immatics in a research report on Thursday, February 19th. TD Cowen began coverage on Immatics in a report on Tuesday, April 28th. They issued a “buy” rating on the stock. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immatics in a report on Tuesday, May 19th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.
View Our Latest Stock Analysis on IMTX
Immatics Company Profile
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
See Also
- Five stocks we like better than Immatics
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics N.V. (NASDAQ:IMTX – Free Report).
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
